Roche to Acquire Carmot Therapeutics for Up to $3.1B
Headline from Geneng News
Roche has agreed to acquire Carmot Therapeutics for up to $3.1 billion, in a deal that catapults the buyer into the scramble among biopharmas to develop new obesity drugs, a specialty that has proven lucrative in recent years.
Geneng News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Roche has agreed to acquire Carmot Therapeutics for up to $3.1 billion, in a deal that catapults the buyer into the scramble among biopharmas to develop new obesity drugs, a specialty that has proven lucrative in recent years.
Roche said Carmot Therapeutics’ research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche’s assets.
Though Carmot’s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Wegovy and Eli Lilly & Co.’s Zepbound.
Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatment that’s sparked a pharma industry gold rush.
Roche said it would buy California-based biotechnology company Carmot Therapeutics for up to $3.1 billion, tapping assets it says have the potential to treat obesity in patients with and without diabetes.
Carmot Therapeutics Inc. was valued at $1.25 billion in May. Half a year later, the company is selling to Swiss drugmaker Roche Holding AG for more than double that amount, fueled by the frenzied demand for obesity medicines.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Roche to Acquire Carmot Therapeutics for Up to $3.1B | Since Then
